logo

XLO

Xilio Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.33 / 10
Outperform

XLO's fundamental score of 7.3/10 indicates robust health, powered by strong PB-ROE, Asset-MV, and Cash-MV factors. However, sub-par current and fixed assets turnover ratios temper the outlook, highlighting efficiency concerns that could cap near-term upside.

Fundamental(7.33)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value0.68
Score1/3
Weight6.55%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight5.75%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight13.16%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight9.81%
1M Return7.79%
PB-ROE
Value-0.68
Score3/3
Weight15.40%
1M Return11.47%
Current assets turnover ratio
Value0.33
Score0/3
Weight-1.79%
1M Return-1.88%
Fixed assets turnover ratio
Value3.57
Score1/3
Weight-1.55%
1M Return-1.64%
Asset-MV
Value-0.50
Score3/3
Weight22.76%
1M Return14.99%
Cash-MV
Value-0.07
Score3/3
Weight30.20%
1M Return16.75%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.29%
1M Return-0.30%
Is XLO fundamentally strong?
  • XLO scores 7.33/10 on fundamentals and holds a Discounted valuation at present. Backed by its -955.40% ROE, -183.90% net margin, -0.65 P/E ratio, -4.51 P/B ratio, and 60.65% earnings growth, these metrics solidify its Outperform investment rating.